Radiolabelled peptides for oncological diagnosis

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue SUPPL.1, 2012, Pages

  Laverman, Peter ^a   Sosabowski, Jane K ^b   Boerman, Otto C ^a   Oyen, Wim J G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Bombesin; CXCR4; Gastrin; GLP 1; Radiolabelled receptor binding peptides

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID EXENDIN 3[LYSINE 40] GA 68; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID GLUTAMYLGLYCINE CHOLECYSTOKININ OCTAPEPTIDE IN 111; BAY 864367; BAY 864367 F 18; BOMBESIN; CHEMOKINE RECEPTOR CXCR4; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ OCTAPEPTIDE; DEMOBESIN 1 TC 99M; DEMOBESIN 2 TC 99M; DEMOGASTRIN 2 TC 99M; DIETHYLENETRIAMINEPENTAACETIC ACID AZ TZ14011 IN 111; DIETHYLENETRIAMINEPENTAACETIC ACID CHOLECYSTOKININ OCTAPEPTIDE IN 111; DIETHYLENETRIAMINEPENTAACETIC ACID EXENDIN 3[LYSINE 40] IN 111; DOTATATE GA 68; EM 3106 B F 18; EM 3106B; GASTRIN I 131; GASTRIN RELEASING PEPTIDE RECEPTOR; MP 2248; MP 2248 IN 111; MP 2346; MP 2346 GA 68; MP 2346 IN 111; N [1,4,8,11 TETRAAZACYCLOTETRADECANYL 1,4 PHENYLENEBIS(METHYLENE)] 2 (AMINOMETHYL)PYRIDINE; N [1,4,8,11 TETRAAZACYCLOTETRADECANYL 1,4 PHENYLENEBIS(METHYLENE)] 2 (AMINOMETHYL)PYRIDINE CU 64; PENTETIC ACID; PENTETREOTIDE; PENTETREOTIDE IN 111; PEPTIDE; PLERIXAFOR; PLERIXAFOR CU 64; RADIOLIGAND; RP 527; RP 527 TC 99M; TETRAXETAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; BOMBESIN RECEPTOR; CHOLECYSTOKININ; CHOLECYSTOKININ RECEPTOR; CXCR4 PROTEIN, HUMAN; DIAGNOSTIC AGENT; DRUG DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE RECEPTOR; LIGAND; OCTREOTIDE; RADIOPHARMACEUTICAL AGENT; SDZ 215 811; SDZ 215-811;

CANCER DIAGNOSIS; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; INSULINOMA; ISOTOPE LABELING; LIGAND BINDING; MOLECULAR IMAGING; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; METABOLISM; NEOPLASM; SCINTISCANNING;

ANIMALS; BOMBESIN; CHOLECYSTOKININ; GLUCAGON-LIKE PEPTIDE 1; HUMANS; LIGANDS; NEOPLASMS; OCTREOTIDE; PENTETIC ACID; PEPTIDES; RADIOPHARMACEUTICALS; RECEPTOR, CHOLECYSTOKININ B; RECEPTORS, BOMBESIN; RECEPTORS, CHOLECYSTOKININ; RECEPTORS, CXCR4; RECEPTORS, GLUCAGON;

EID: 84863796755     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-2014-7     Document Type: Review

References (132)

1. Ivy AC, Oldberg E. A hormone reaction for gallbladder contraction and evacuation. Am J Physiol. 1928;86:599-613.
2. Vanderhaeghen JJ, Signeau JC, Gepts W. New peptide in vertebrate CNS reacting with antigastrin antibodies. Nature. 1975;257:604-5.
3. Noble F, Wank SA, Crawley JN, Bradwejn J, Seroogy KB, Hamon M, et al. International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. Pharmacol Rev. 1999;51:745-81.
4. Noble F, Roques BP. CCK-B receptor: chemistry, molecular biology, biochemistry and pharmacology. Prog Neurobiol. 1999;58:349-79.
5. Behr TM, Jenner N, Béhé M, Angerstein C, Gratz S, Raue F, et al. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors. J Nucl Med. 1999;40:1029-44.
6. Wank SA, Pisegna JR, de Weerth A. Cholecystokinin receptor family. Molecular cloning, structure, and functional expression in rat, guinea pig, and human. Ann N Y Acad Sci. 1994;713:49-66.
7. Sankaran H, Goldfine ID, Deveney CW, Wong KY, Williams JA. Binding of cholecystokinin to high-affinity receptors on isolated rat pancreatic acini. J Biol Chem. 1980;255:1849-53.
8. Innis RB, Snyder SH. Distinct cholecystokinin receptors in brain and pancreas. Proc Natl Acad Sci USA. 1980;77:6917-21.
9. Hellmich MR, Rui XL, Hellmich HL, Fleming RY, Evers BM, Townsend Jr CM. Human colorectal cancers express a constitutively active cholecystokinin-B/ gastrin receptor that stimulates cell growth. J Biol Chem. 2000;275:32122-8.
10. Reubi JC, Waser B. Unexpected high incidence of cholecystokinin-B/gastrin receptors in human medullary thyroid carcinomas. Int J Cancer. 1996;67:644-7.
11. Reubi JC, Schaer JC, Waser B. Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res. 1997;57:1377-86.
12. Smith JP, Verderame MF, McLaughlin P, Martenis M, Ballard E, Zagon IS. Characterization of the CCK-C (cancer) receptor in human pancreatic cancer. Int J Mol Med. 2002;10:689-94.
13. Korner M, Waser B, Reubi JC, Miller LJ. CCK(2) receptor splice variant with intron 4 retention in human gastrointestinal and lung tumours. J Cell Mol Med. 2010;14:933-43.
14. Behr TM, Jenner N, Radetzky S, Béhé M, Gratz S, Yucekent S, et al. Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. Eur J Nucl Med. 1998;25:424-30.
15. Reubi JC, Waser B, Schaer JC, Laederach U, Erion J, Srinivasan A, et al. Unsulfated DTPA- and DOTA-CCk analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo. Eur J Nucl Med. 1998;25:481-90.
16. de Jong M, Bakker WH, Bernard BF, Valkema R, Kwekkeboom DJ, Reubi JC, et al. Preclinical and initial clinical evaluation of 111In-labeled nonsulfated CCK8 analog: a peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med. 1999;40:2081-7.
17. Laverman P, Béhé M, Oyen WJ, Willems PH, Corstens FH, Behr TM, et al. Two technetium-99m-labeled cholecystokinin-8 (CCK8) peptides for scintigraphic imaging of CCK receptors. Bioconjug Chem. 2004;15:561-8.
18. Laverman P, Roosenburg S, Gotthardt M, Park JS, Oyen WJG, de Jong M, et al. Targeting of a CCK2 receptor splice variant with In-111-labelled cholecystokinin-8 (CCK8) and In-111-labelled minigastrin. Eur J Nucl Med Mol Imaging. 2008;35:386-92.
19. Aloj L, Caraco C, Panico M, Zannetti A, Del Vecchio S, Tesauro D, et al. In vitro and in vivo evaluation of In-111-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging. J Nucl Med. 2004;45:485-94.
20. Aloj L, Panico M, Caraco C, Del Vecchio S, Arra C, Affuso A, et al. In vitro and in vivo characterization of indium-111 and technetium-99m labeled CCK-8 derivatives for CCK-B receptor imaging. Cancer Biother Radiopharm. 2004;19:93-8.
21. Béhé M, Becker W, Gotthardt M, Angerstein C, Behr TM. Improved kinetic stability of DTPA-dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives. Eur J Nucl Med Mol Imaging. 2003;30:1140-6.
22. Nock BA, Maina T, Béhé M, Nikolopoulou A, Gotthardt M, Schmitt JS, et al. CCK-2/gastrin receptor-targeted tumor imaging with (99m)Tc-labeled minigastrin analogs. J Nucl Med. 2005;46:1727-36.
23. Béhé M, Kluge G, Becker W, Gotthardt M, Behr TM. Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys. J Nucl Med. 2005;46:1012-5.
24. Mather SJ, McKenzie AJ, Sosabowski JK, Morris TM, Ellison D, Watson SA. Selection of radiolabeled gastrin analogs for peptide receptor-targeted radionuclide therapy. J Nucl Med. 2007;48:615-22.
25. Roosenburg S, Laverman P, Joosten L, Eek A, Oyen WJ, De JM, et al. Stabilized (111)in-labeled sCCK8 analogues for targeting CCK2-receptor positive tumors: synthesis and evaluation. Bioconjug Chem. 2010;21:663-70.
26. Good S, Walter MA, Waser B, Wang X, Müller-Brand J, Béhé MP, et al. Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours. Eur J Nucl Med Mol Imaging. 2008;35:1868-77.
27. Dijkgraaf I, Kruijtzer JAW, Frielink C, Soede AC, Hilbers HW, Oyen WJG, et al. Synthesis and biological evaluation of potent alpha(v)beta(3)-integrin receptor antagonists. Nucl Med Biol. 2006;33:953-61.
28. Haubner R. alpha(v)beta(3)-integrin imaging: a new approach to characterise angiogenesis? Eur J Nucl Med Mol Imaging. 2006;33:S54-63.
29. von Guggenberg E, Sallegger W, Helbok A, Ocak M, King R, Mather SJ, et al. Cyclic minigastrin analogues for gastrin receptor scintigraphy with technetium-99m: preclinical evaluation. J Med Chem. 2009;52:4786-93.
30. von Guggenberg E, Rangger C, Sosabowski J, Laverman P, Reubi JC, Virgolini IJ, et al. Preclinical evaluation of radiolabeled DOTA-derivatized cyclic minigastrin analogs for targeting cholecystokinin receptor expressing malignancies. Mol Imaging Biol. 2011. doi: 10.1007/s11307-011-0506-2.
31. Sosabowski JK, Matzow T, Foster JM, Finucane C, Ellison D, Watson SA, et al. Targeting of CCK-2 receptor-expressing tumors using a radiolabeled divalent gastrin peptide. J Nucl Med. 2009;50:2082-9.
32. Laverman P, Joosten L, Eek A, Roosenburg S, Peitl PK, Maina T, et al. Comparative biodistribution of 12 (111)In-labelled gastrin/CCK2 receptor-targeting peptides. Eur J Nucl Med Mol Imaging. 2011;38:1410-6.
33. Aloj L, Aurilio M, Rinaldi V, D'ambrosio L, Tesauro D, Peitl PK, et al. Comparison of the binding and internalization properties of 12 DOTA-coupled and (111)In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607. Eur J Nucl Med Mol Imaging. 2011;38:1417-25.
34. Ocak M, Helbok A, Rangger C, Peitl PK, Nock BA, Morelli G, et al. Comparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607. Eur J Nucl Med Mol Imaging. 2011;38:1426-35.
35. Kolenc-Peitl P, Mansi R, Tamma M, Gmeiner-Stopar T, Sollner-Dolenc M, Waser B, et al. Highly improved metabolic stability and pharmacokinetics of indium-111-DOTA-gastrin conjugates for targeting of the gastrin receptor. J Med Chem. 2011;54:2602-9.
36. Béhé M, Behr TM. Cholecystokinin-13 (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies. Biopolymers. 2002;66:399-418.
37. Gotthardt M, Béhé MP, Beuter D, Battmann A, Bauhofer A, Schurrat T, et al. Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2006;33:1273-9.
38. Fröberg AC, de Jong M, Nock BA, Breeman WAP, Erion JL, Maina T, et al. Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2009;36:1265-72.
39. Kwekkeboom DJ, Bakker WH, Kooij PP, Erion J, Srinivasan A, De JM, et al. Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma. Eur J Nucl Med. 2000;27:1312-7.
40. Behr TM, Béhé MP. Cholecystokinin-B/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med. 2002;32:97-109.
41. Breeman WAP, Fröberg AC, De Blois E, van Gameren A, Melis M, de Jong M, et al. Optimised labeling, preclinical and initial clinical. Aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides. Nucl Med Biol. 2008;35:839-49.
42. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2003;30:781-93.
43. Korner M, Stockli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med. 2007;48:736-43.
44. Gotthardt M, Fischer M, Naeher I, Holz JB, Jungclas H, Fritsch HW, et al. Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results. Eur J Nucl Med Mol Imaging. 2002;29:597-606.
45. Wild D, Béhé M, Wicki A, Storch D, Waser B, Gotthardt M, et al. [Lys(40) (Ahx-DTPA-In-111)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med. 2006;47:2025-33.
46. Brom M, Oyen WJG, Joosten L, Gotthardt M, Boerman OC. (68)Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET. Eur J Nucl Med Mol Imaging. 2010;37:1345-55.
47. Wild D, Wicki A, Mansi R, Béhé M, Keil B, Bernhardt P, et al. Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT. J Nucl Med. 2010;51:1059-67.
48. Gao H, Niu G, Yang M, Quan Q, Ma Y, Murage EN, et al. PET of insulinoma using (18)F-FBEM-EM3106B, a new GLP-1 analogue. Mol Pharm. 2011;8:1775-82.
49. Wild D, Macke H, Christ E, Gloor B, Reubi JC. Glucagon-like peptide 1-receptor scans to localize occult insulinomas. N Engl J Med. 2008;359:766-8.
50. Christ E, Wild D, Forrer F, Brandle M, Sahli R, Clerici T, et al. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metab. 2009;94:4398-405.
51. Wild D, Christ E, Caplin ME, Kurzawinski TR, Forrer F, Brandle M, et al. Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. J Nucl Med. 2011;52:1073-8.
52. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 1996;272:872-7.
53. Müller A, Homey B, Soto H, Ge NF, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50-6.
54. Hanaoka H, Mukai T, Tamamura H, Mori T, Ishino S, Ogawa K, et al. Development of a In-111-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging tumors. Nucl Med Biol. 2006;33:489-94.
55. Jacobson O, Weiss ID, Kiesewetter DO, Farber JM, Chen X. PET of tumor CXCR4 expression with 4-18F-T140. J Nucl Med. 2010;51:1796-804.
56. Jacobson O, Weiss ID, Szajek L, Farber JM, Kiesewetter DO. 64Cu-AMD3100 - a novel imaging agent for targeting chemokine receptor CXCR4. Bioorg Med Chem. 2009;17:1486-93.
57. Nimmagadda S, Pullambhatla M, Stone K, Green G, Bhujwalla ZM, Pomper MG. Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomography. Cancer Res. 2010;70:3935-44.
58. Weiss ID, Jacobson O, Kiesewetter DO, Jacobus JP, Szajek LP, Chen X, et al. Positron emission tomography imaging of tumors expressing the human chemokine receptor CXCR4 in mice with the use of (64)Cu-AMD3100. Mol Imaging Biol. 2011. doi: 10.1007/s11307-010-0466-y.
59. De Silva RA, Peyre K, Pullambhatla M, Fox JJ, Pomper MG, Nimmagadda S. Imaging CXCR4 expression in human cancer xenografts: evaluation of monocyclam 64Cu-AMD3465. J Nucl Med. 2011;52:986-93.
60. Reubi JC, Wenger S, Schmuckli-Maurer J, Schaer JC, Gugger M. Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6-14). Clin Cancer Res. 2002;8:1139-46.
61. Reubi JC, Korner M, Waser B, Mazzucchelli L, Guillou L. High expression of peptide receptors as a novel target in gastrointestinal stromal tumours. Eur J Nucl Med Mol Imaging. 2004;31:803-10.
62. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24:389-427.
63. Baidoo KE, Lin KS, Zhan Y, Finley P, Scheffel U, Wagner Jr HN. Design, synthesis, and initial evaluation of high-affinity technetium bombesin analogues. Bioconjug Chem. 1998;9:218-25.
64. Lin KS, Luu A, Baidoo KE, Hashemzadeh-Gargari H, Chen MK, Brenneman K, et al. A new high affinity technetium-99m-bombesin analogue with low abdominal accumulation. Bioconjug Chem. 2005;16:43-50.
65. Lin KS, Luu A, Baidoo KE, Hashemzadeh-Gargari H, Chen MK, Pili R, et al. A new high affinity technetium analogue of bombesin containing DTPA as a pharmacokinetic modifier. Bioconjug Chem. 2004;15:1416-23.
66. Gali H, Hoffman TJ, Sieckman GL, Owen NK, Katti KV, Volkert WA. Synthesis, characterization, and labeling with 99mTc/188Re of peptide conjugates containing a dithia-bisphosphine chelating agent. Bioconjug Chem. 2001;12:354-63.
67. Karra SR, Schibli R, Gali H, Katti KV, Hoffman TJ, Higginbotham C, et al. 99mTc-labeling and in vivo studies of a bombesin analogue with a novel water-soluble dithiadiphosphine-based bifunctional chelating agent. Bioconjug Chem. 1999;10:254-60.
68. Smith CJ, Gali H, Sieckman GL, Higginbotham C, Volkert WA, Hoffman TJ. Radiochemical investigations of (99m)Tc-N(3)S-X-BBN[7-14]NH(2): an in vitro/in vivo structure-activity relationship study where X = 0-, 3-, 5-, 8-, and 11-carbon tethering moieties. Bioconjug Chem. 2003;14:93-102.
69. van de Wiele C, Dumont F, Vanden Broecke R, Oosterlinck W, Cocquyt V, Serreyn R, et al. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur J Nucl Med. 2000;27:1694-9.
70. van de Wiele C, Dumont F, Dierckx RA, Peers SH, Thornback JR, Slegers G, et al. Biodistribution and dosimetry of (99m)Tc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignancies. J Nucl Med. 2001;42:1722-7.
71. Wang LH, Coy DH, Taylor JE, Jiang NY, Moreau JP, Huang SC, et al. des-Met carboxyl-terminally modified analogues of bombesin function as potent bombesin receptor antagonists, partial agonists, or agonists. J Biol Chem. 1990;265:15695-703.
72. Nock B, Nikolopoulou A, Chiotellis E, Loudos G, Maintas D, Reubi JC, et al. [99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med Mol Imaging. 2003;30:247-58.
73. Nock BA, Nikolopoulou A, Galanis A, Cordopatis P, Waser B, Reubi JC, et al. Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study. J Med Chem. 2005;48:100-10.
74. Ferro-Flores G, de Murphy CA, Rodriguez-Cortes J, Pedraza-Lopez M, Ramirez-Iglesias MT. Preparation and evaluation of 99mTc-EDDA/HYNIC-[Lys 3]-bombesin for imaging gastrin-releasing peptide receptor-positive tumours. Nucl Med Commun. 2006;27:371-6.
75. La Bella R, Garcia-Garayoa E, Langer M, Blauenstein P, Beck-Sickinger AG, Schubiger PA. In vitro and in vivo evaluation of a 99mTc(I)-labeled bombesin analogue for imaging of gastrin releasing peptide receptor-positive tumors. Nucl Med Biol. 2002;29:553-60.
76. Garcia Garayoa E, Ruegg D, Blauenstein P, Zwimpfer M, Khan IU, Maes V, et al. Chemical and biological characterization of new Re(CO)3/[99mTc](CO)3 bombesin analogues. Nucl Med Biol. 2007;34:17-28.
77. Garcia Garayoa E, Schweinsberg C, Maes V, Ruegg D, Blanc A, Blauenstein P, et al. New [99mTc]bombesin analogues with improved biodistribution for targeting gastrin releasing-peptide receptor-positive tumors. Q J Nucl Med Mol Imaging. 2007;51:42-50.
78. Brans L, Maes V, Garcia-Garayoa E, Schweinsberg C, Daepp S, Blauenstein P, et al. Glycation methods for bombesin analogs containing the (NalphaHis)Ac chelator for 99mTc(CO)3 radiolabeling. Chem Biol Drug Des. 2008;72:496-506.
79. Garcia Garayoa E, Schweinsberg C, Maes V, Brans L, Blauenstein P, Tourwe DA, et al. Influence of the molecular charge on the biodistribution of bombesin analogues labeled with the [99mTc(CO)3]-core. Bioconjug Chem. 2008;19:2409-16.
80. Schweinsberg C, Maes V, Brans L, Blauenstein P, Tourwe DA, Schubiger PA, et al. Novel glycated [99mTc(CO)3]-labeled bombesin analogues for improved targeting of gastrin-releasing peptide receptor-positive tumors. Bioconjug Chem. 2008;19:2432-9.
81. Smith CJ, Sieckman GL, Owen NK, Hayes DL, Mazuru DG, Kannan R, et al. Radiochemical investigations of gastrin-releasing peptide receptor-specific [(99m)Tc(X)(CO)3-Dpr-Ser-Ser-Ser-Gln-Trp-Ala-Val-Gly-His-Leu-Met-(NH2)] in PC-3, tumor-bearing, rodent models: syntheses, radiolabeling, and in vitro/in vivo studies where Dpr = 2,3-diaminopropionic acid and X = H2O or P(CH2OH)3. Cancer Res. 2003;63:4082-8.
82. Retzloff LB, Heinzke L, Figureoa SD, Sublett SV, Ma L, Sieckman GL, et al. Evaluation of [99mTc-(CO)3-X-Y-bombesin(7-14)NH2] conjugates for targeting gastrin-releasing peptide receptors overexpressed on breast carcinoma. Anticancer Res. 2010;30:19-30.
83. Dapp S, Garayoa EG, Maes V, Brans L, Tourwe DA, Müller C, et al. PEGylation of (99m)Tc-labeled bombesin analogues improves their pharmacokinetic properties. Nucl Med Biol. 2011;38:997-1009.
84. Breeman WA, Hofland LJ, de Jong M, Bernard BF, Srinivasan A, Kwekkeboom DJ, et al. Evaluation of radiolabelled bombesin analogues for receptor-targeted scintigraphy and radiotherapy. Int J Cancer. 1999;81:658-65.
85. Breeman WA, de Jong M, Bernard BF, Kwekkeboom DJ, Srinivasan A, van der Pluijm ME, et al. Pre-clinical evaluation of [(111)In-DTPA-Pro(1), Tyr(4)]bombesin, a new radioligand for bombesin-receptor scintigraphy. Int J Cancer. 1999;83:657-63.
86. Breeman WA, de Jong M, Erion JL, Bugaj JE, Srinivasan A, Bernard BF, et al. Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med. 2002;43:1650-6.
87. de Visser M, Bernard HF, Erion JL, Schmidt MA, Srinivasan A, Waser B, et al. Novel 111In-labelled bombesin analogues for molecular imaging of prostate tumours. Eur J Nucl Med Mol Imaging. 2007;34:1228-38.
88. Hoffman TJ, Gali H, Smith CJ, Sieckman GL, Hayes DL, Owen NK, et al. Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells. J Nucl Med. 2003;44:823-31.
89. Zhang H, Chen J, Waldherr C, Hinni K, Waser B, Reubi JC, et al. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer Res. 2004;64:6707-15.
90. Zhang H, Schuhmacher J, Waser B, Wild D, Eisenhut M, Reubi JC, et al. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours. Eur J Nucl Med Mol Imaging. 2007;34:1198-208.
91. Schuhmacher J, Zhang H, Doll J, Macke HR, Matys R, Hauser H, et al. GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68Ga-labeled bombesin(6-14) analog. J Nucl Med. 2005;46:691-9.
92. Lantry LE, Cappelletti E, Maddalena ME, Fox JS, Feng W, Chen J, et al. 177Lu-AMBA: synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med. 2006;47:1144-52.
93. Schroeder RP, Müller C, Reneman S, Melis ML, Breeman WA, De Blois E, et al. A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues. Eur J Nucl Med Mol Imaging. 2010;37:1386-96.
94. Abd-Elgaliel WR, Gallazzi F, Garrison JC, Rold TL, Sieckman GL, Figueroa SD, et al. Design, synthesis, and biological evaluation of an antagonist-bombesin analogue as targeting vector. Bioconjug Chem. 2008;19:2040-8.
95. Mansi R, Wang X, Forrer F, Kneifel S, Tamma ML, Waser B, et al. Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides. Clin Cancer Res. 2009;15:5240-9.
96. Mansi R, Wang X, Forrer F, Waser B, Cescato R, Graham K, et al. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging. 2011;38:97-107.
97. Schroeder RP, van Weerden WM, Krenning EP, Bangma CH, Berndsen S, Grievink-de Ligt CH, et al. Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts. Eur J Nucl Med Mol Imaging. 2011;38:1257-66.
98. Liu Z, Niu G, Wang F, Chen X. (68)Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging. Eur J Nucl Med Mol Imaging. 2009;36:1483-94.
99. Hoffman TJ, Smith CJ. True radiotracers: Cu-64 targeting vectors based upon bombesin peptide. Nucl Med Biol. 2009;36:579-85.
100. Rogers BE, Bigott HM, McCarthy DW, la Manna D, Kim J, Sharp TL, et al. MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue. Bioconjug Chem. 2003;14:756-63.
101. Chen X, Park R, Hou Y, Tohme M, Shahinian AH, Bading JR, et al. MicroPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. J Nucl Med. 2004;45:1390-7.
102. Rogers BE, Manna DD, Safavy A. In vitro and in vivo evaluation of a 64Cu-labeled polyethylene glycol-bombesin conjugate. Cancer Biother Radiopharm. 2004;19:25-34.
103. Yan Y, Chen K, Yang M, Sun X, Liu S, Chen X. A new 18F-labeled BBN-RGD peptide heterodimer with a symmetric linker for prostate cancer imaging. Amino Acids. 2010;41:439-47.
104. Prasanphanich AF, Nanda PK, Rold TL, Ma L, Lewis MR, Garrison JC, et al. [64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proc Natl Acad Sci USA. 2007;104:12462-7.
105. Gasser G, Tjioe L, Graham B, Belousoff MJ, Juran S, Walther M, et al. Synthesis, copper(II) complexation, (64)Cu-labeling, and bioconjugation of a new bis(2-pyridylmethyl) derivative of 1,4,7-triazacyclononane. Bioconjug Chem. 2008;19:719-30.
106. Prasanphanich AF, Retzloff L, Lane SR, Nanda PK, Sieckman GL, Rold TL, et al. In vitro and in vivo analysis of [(64)Cu-NO2A-8-Aoc-BBN(7-14)NH(2)]: a site-directed radiopharmaceutical for positron-emission tomography imaging of T-47D human breast cancer tumors. Nucl Med Biol. 2009;36:171-81.
107. Garrison JC, Rold TL, Sieckman GL, Figueroa SD, Volkert WA, Jurisson SS, et al. In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems. J Nucl Med. 2007;48:1327-37.
108. Lane SR, Nanda P, Rold TL, Sieckman GL, Figueroa SD, Hoffman TJ, et al. Optimization, biological evaluation and microPET imaging of copper-64-labeled bombesin agonists, [64Cu-NO2A-(X)-BBN(7-14)NH2], in a prostate tumor xenografted mouse model. Nucl Med Biol. 2010;37:751-61.
109. Parry JJ, Kelly TS, Andrews R, Rogers BE. In vitro and in vivo evaluation of 64Cu-labeled DOTA-linker-bombesin(7-14) analogues containing different amino acid linker moieties. Bioconjug Chem. 2007;18:1110-7.
110. Di Bartolo NM, Sargeson AM, Donlevy TM, Smith SV. Synthesis of a new cage ligand, SarAr, and its complexation with selected transition metal ions for potential use in radioimaging. J Chem Soc Dalton Trans. 2001;15:2303-9.
111. Lears KA, Ferdani R, Liang K, Zheleznyak A, Andrews R, Sherman CD, et al. In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer. J Nucl Med. 2011;52:470-7.
112. Zhang X, Cai W, Cao F, Schreibmann E, Wu Y, Wu JC, et al. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med. 2006;47:492-501.
113. Hohne A, Mu L, Honer M, Schubiger PA, Ametamey SM, Graham K, et al. Synthesis, 18F-labeling, and in vitro and in vivo studies of bombesin peptides modified with silicon-based building blocks. Bioconjug Chem. 2008;19:1871-9.
114. Li ZB, Wu Z, Chen K, Ryu EK, Chen X. 18F-labeled BBN-RGD heterodimer for prostate cancer imaging. J Nucl Med. 2008;49:453-61.
115. Liu Z, Yan Y, Chin FT, Wang F, Chen X. Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using 18F-labeled PEGylated RGD-bombesin heterodimer 18F-FB-PEG3-Glu-RGD-BBN. J Med Chem. 2009;52:425-32.
116. Mu L, Honer M, Becaud J, Martic M, Schubiger PA, Ametamey SM, et al. In vitro and in vivo characterization of novel 18F-labeled bombesin analogues for targeting GRPR-positive tumors. Bioconjug Chem. 2010;21:1864-71.
117. Honer M, Mu L, Stellfeld T, Graham K, Martic M, Fischer CR, et al. 18F-labeled bombesin analog for specific and effective targeting of prostate tumors expressing gastrin-releasing peptide receptors. J Nucl Med. 2011;52:270-8.
118. Yang M, Gao H, Zhou Y, Ma Y, Quan Q, Lang L, et al. F-18-labeled GRPR agonists and antagonists: a comparative study in prostate cancer imaging. Theranostics. 2011;1:220-9.
119. Liu Z, Yan Y, Liu S, Wang F, Chen X. (18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer. Bioconjug Chem. 2009;20:1016-25.
120. Bodei L, Ferrari M, Nunn A, Llull J, Cremonesi M, Martano L, et al. 177Lu-AMBA bombesin analogue in hormone refractory prostate cancer patients: a phase I escalation study with single-cycle administrations. Eur J Nucl Med Mol Imaging. 2007;34:S221.
121. Scopinaro F, Varvarigou AD, Ussof W, De Vincentis G, Sourlingas TG, Evangelatos GP, et al. Technetium labeled bombesin-like peptide: preliminary report on breast cancer uptake in patients. Cancer Biother Radiopharm. 2002;17:327-35.
122. Varvarigou AD, Scopinaro F, Leondiadis L, Corleto V, Schillaci O, De Vincentis G, et al. Synthesis, chemical, radiochemical and radiobiological evaluation of a new 99mTc-labelled bombesin-like peptide. Cancer Biother Radiopharm. 2002;17:317-26.
123. Scopinaro F, De Vincentis G, Varvarigou AD, Laurenti C, Iori F, Remediani S, et al. 99mTc-bombesin detects prostate cancer and invasion of pelvic lymph nodes. Eur J Nucl Med Mol Imaging. 2003;30:1378-82.
124. Scopinaro F, De Vincentis G, Corazziari E, Massa R, Osti M, Pallotta N, et al. Detection of colon cancer with 99mTc-labeled bombesin derivative (99mTc-leu13-BN1). Cancer Biother Radiopharm. 2004;19:245-52.
125. Fröberg A, Visser M, Maina T, Erion J, de Swart J, de Jong M, et al. Are GRP-receptors present in the human pancreas? J Nucl Med. 2006;47 Suppl 1:429P.
126. Meyer GJ, Macke H, Schuhmacher J, Knapp WH, Hofmann M. 68Ga-labelled DOTA-derivatised peptide ligands. Eur J Nucl Med Mol Imaging. 2004;31:1097-104.
127. Hofmann M, Machtens S, Stief C, Maecke H, Boerner AR, Knapp WH. Feasibility of Ga-68-DOTABOM PET in prostate carcinoma patients. Eur J Nucl Med Mol Imaging. 2004;31:S253.
128. Maecke HR, Hofmann M, Haberkorn U. (68)Ga-labeled peptides in tumor imaging. J Nucl Med. 2005;46 Suppl 1:172S-8S.
129. Dimitrakopoulou-Strauss A, Hohenberger P, Haberkorn U, Macke HR, Eisenhut M, Strauss LG. 68Ga-labeled bombesin studies in patients with gastrointestinal stromal tumors: comparison with 18F-FDG. J Nucl Med. 2007;48:1245-50.
130. Schaefer N, Valencia R, Borkowski S, Geissler E, Kristiansen G, Rohde B, et al. Comparison of BAY 86-4367, a new F-18 labeled bombesin analog, with F-18-ethyl-choline in recurrent and primary prostate cancer patients. J Nucl Med. 2011;52 Suppl 1:40.
131. Beer M, Montani M, Gerhardt J, Wild PJ, Hany TF, Hermanns T, et al. Profiling gastrin-releasing peptide receptor in prostate tissues: clinical implications and molecular correlates. Prostate. 2011. doi: 10.1002/pros.21434
132. Schroeder RP, van Weerden WM, Bangma C, Krenning EP, de Jong M. Peptide receptor imaging of prostate cancer with radiolabelled bombesin analogues. Methods. 2009;48:200-4.